成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ChemicalBook >> journal list >> Recent Results in Cancer Research >>article

Recent Results in Cancer Research

Download PDF

Axitinib (AG-013736).

Published:1 January 2010 DOI: 10.1007/978-3-642-01222-8_3 PMID: 20072829
Ronan Joseph Kelly, Olivier Rixe

Abstract

The vascular endothelial growth factor (VEGF)/VEGF receptor tyrosine kinase (RTK) signaling pathway plays a pivotal role in tumor angiogenesis. Neovascularization promotes increased tumor cell proliferation, survival and metasasis. Many antiangiogenic agents including multi-RTK inhibitors are either approved or are undergoing testing in clinical trials. Axitinib is a potent and selective inhibitor of VEGF RTK 1, 2, and 3. This chapter discusses the stucture of axitinib as well as its toxicities and drug interactions. Important preclinical and clinical data for axitinib are presented including findings from phase II studies in many tumor types including malignant melanoma and renal, pancreatic, thyroid, breast, lung and colorectal carcinomas. Ongoing phase III studies in pancreatic and metastatic renal cell carcinoma will ultimately define the therapeutic role of this targeted agent.

Substances (4)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Axitinib 319460-85-0 C22H18N4OS 480 suppliers $39.00-$1154.00
HUMAN VEGF165 127464-60-2 NULL 135 suppliers $98.40-$908.00
VEGF Receptor 2 10 suppliers Inquiry
RTK TOTAL 7-PLEX 4 suppliers Inquiry

Similar articles

IF:4.6

Clinical pharmacology of axitinib.

Clinical Pharmacokinetics Ying Chen, Michael A Tortorici,etc Published: 1 September 2013